New Risk • May 24
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.2% Last year net profit margin: 9.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (0.2% net profit margin). Revenue is less than US$5m (₹255m revenue, or US$2.7m). Market cap is less than US$100m (₹1.17b market cap, or US$12.2m). Duyuru • May 18
Aspira Pathlab & Diagnostics Limited to Report Q4, 2026 Results on May 23, 2026 Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 23, 2026 Valuation Update With 7 Day Price Move • May 13
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹77.07, the stock trades at a trailing P/E ratio of 55.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 141% over the past three years. Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹64.74, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 97% over the past three years. New Risk • Mar 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$10m (₹644.1m market cap, or US$7.01m). Minor Risk Revenue is less than US$5m (₹242m revenue, or US$2.6m). Duyuru • Mar 07
Aspira Pathlab & Diagnostics Limited Announces Resignation of Krupali Shah as Company Secretary Cum Compliance Officer, Effective March 8, 2026 Aspira Pathlab & Diagnostics Limited has announced that Ms. Krupali Shah, (Membership No: A70473) Company Secretary cum Compliance Officer of the Company has tendered her resignation due to personal reasons and she will be relieved from her services with effect from March 8, 2026. Reported Earnings • Feb 11
Third quarter 2026 earnings released: ₹1.52 loss per share (vs ₹0.30 profit in 3Q 2025) Third quarter 2026 results: ₹1.52 loss per share (down from ₹0.30 profit in 3Q 2025). Revenue: ₹52.5m (down 2.9% from 3Q 2025). Net loss: ₹15.6m (down ₹18.7m from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Duyuru • Feb 07
Aspira Pathlab & Diagnostics Limited Appoints Kiran Raghavendra Awasthi as Non-Executive, Independent Director Effective November 12, 2025 Aspira Pathlab & Diagnostics Limited has appointed Mrs. Kiran Raghavendra Awasthi (DIN: 09066721) as Non-Executive, Independent Director for the first term of five consecutive years with effect from November 12, 2025. The appointment was approved by the members of the company through Postal Ballot (remote e-voting) by a Special Resolution. Mrs. Kiran Awasthi is a Chartered Accountant and is a senior partner at AMRG & Associates with over 28 years of experience in the field of Finance, Audit, Accounting & Taxation. She also serves on Board of Raj Oil Mills Limited as Independent Director. She has wide and rich exposure in financial management, governance and analytical leadership with a strong commitment to professionalism and integrity. Duyuru • Feb 04
Aspira Pathlab & Diagnostics Limited to Report Q3, 2026 Results on Feb 10, 2026 Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2026 results on Feb 10, 2026 Duyuru • Jan 05
Aspira Pathlab & Diagnostics Limited Announces Demise of Independent Director Dr. Alaka Keshav Deshpande and Changes in Board Committee Composition, Effective on December 30, 2025 Aspira Pathlab & Diagnostics Limited announced the demise of Dr. Alaka Keshav Deshpande, Independent Director aged 79 years, who passed away on December 30, 2025. Owing to the unfortunate demise of Dr. Alaka Keshav Deshpande, she ceases from the office of Independent Director of the Company effective from December 30, 2025 and also ceases the Membership held in the following Committees of Board: Audit Committee - Member, Nomination & Remuneration Committee - Member, Stakeholder Relationship Committee - Member. Reported Earnings • Nov 14
Second quarter 2026 earnings released: EPS: ₹1.78 (vs ₹0.30 in 2Q 2025) Second quarter 2026 results: EPS: ₹1.78 (up from ₹0.30 in 2Q 2025). Revenue: ₹82.3m (up 52% from 2Q 2025). Net income: ₹18.4m (up 500% from 2Q 2025). Profit margin: 22% (up from 5.7% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 04
Aspira Pathlab & Diagnostics Limited to Report Q2, 2026 Results on Nov 12, 2025 Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2026 results on Nov 12, 2025 Valuation Update With 7 Day Price Move • Oct 03
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹71.68, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 45x in the Healthcare industry in India. Total returns to shareholders of 57% over the past three years. New Risk • Oct 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹702.7m market cap, or US$7.92m). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Revenue is less than US$5m (₹226m revenue, or US$2.5m). Duyuru • Sep 26
Aspira Pathlab & Diagnostics Limited Appoints Dr. Alaka Deshpande as Independent Director Aspira Pathlab & Diagnostics Limited announced that at its AGM held on September 26, 2025, shareholders approved the appointment of Dr. Alaka Deshpande as independent director for the term of 3 years. Duyuru • Sep 01
Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 26, 2025 Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 26, 2025, at 14:00 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2026 earnings released: EPS: ₹0.41 (vs ₹0.05 in 1Q 2025) First quarter 2026 results: EPS: ₹0.41 (up from ₹0.05 in 1Q 2025). Revenue: ₹53.6m (up 16% from 1Q 2025). Net income: ₹4.22m (up ₹3.74m from 1Q 2025). Profit margin: 7.9% (up from 1.0% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Duyuru • Aug 02
Aspira Pathlab & Diagnostics Limited to Report Q1, 2026 Results on Aug 12, 2025 Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2026 results on Aug 12, 2025 Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹61.95, the stock trades at a trailing P/E ratio of 31.5x. Average trailing P/E is 49x in the Healthcare industry in India. Total returns to shareholders of 18% over the past three years. Valuation Update With 7 Day Price Move • Jun 12
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹61.80, the stock trades at a trailing P/E ratio of 31.4x. Average trailing P/E is 47x in the Healthcare industry in India. Total returns to shareholders of 18% over the past three years. Reported Earnings • May 20
Full year 2025 earnings released: EPS: ₹1.97 (vs ₹2.60 loss in FY 2024) Full year 2025 results: EPS: ₹1.97 (up from ₹2.60 loss in FY 2024). Revenue: ₹223.9m (up 70% from FY 2024). Net income: ₹20.2m (up ₹46.9m from FY 2024). Profit margin: 9.0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. New Risk • May 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹548.1m market cap, or US$6.41m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$5m (₹200m revenue, or US$2.3m). Duyuru • May 10
Aspira Pathlab & Diagnostics Limited to Report Q4, 2025 Results on May 16, 2025 Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2025 results on May 16, 2025 Reported Earnings • Feb 08
Third quarter 2025 earnings released: EPS: ₹0.30 (vs ₹0.72 loss in 3Q 2024) Third quarter 2025 results: EPS: ₹0.30 (up from ₹0.72 loss in 3Q 2024). Revenue: ₹55.0m (up 59% from 3Q 2024). Net income: ₹3.06m (up ₹10.5m from 3Q 2024). Profit margin: 5.6% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance. Duyuru • Jan 31
Aspira Pathlab & Diagnostics Limited to Report Q3, 2025 Results on Feb 07, 2025 Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2025 results on Feb 07, 2025 Duyuru • Jan 22
Aspira Pathlab & Diagnostics Limited Announces Resignation of Avinash Mahajan as Non-Executive and Independent Director Aspira Pathlab & Diagnostics Limited informed that Mr. Avinash Mahajan has tendered his resignation as Non-Executive, Independent Director of the Company. Consequently, he also ceases to be the member of Audit Committee, Stakeholder Relationship Committee and Chairman of the Nomination & Remuneration Committee of the Company. Reason for change: Mr. Avinash Mahajan shall be completing 75 years of age on July 05, 2025. Pursuant to applicability of Regulation 17(1A) of SEBI (LODR) Regulations,2015 and consistent with the principles of good corporate governance, Mr. Avinash Mahajan has tendered his resignation as an Independent director and accordingly from Board Committees effective immediately. Mr. Avinash Mahajan has confirmed that there are no material reasons for his resignation. Date of cessation: January 22, 2025. New Risk • Dec 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$10m (₹680.1m market cap, or US$8.01m). Minor Risk Revenue is less than US$5m (₹152m revenue, or US$1.8m). Duyuru • Oct 31
Aspira Pathlab & Diagnostics Limited to Report Q2, 2025 Results on Nov 12, 2024 Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2025 results on Nov 12, 2024 Duyuru • Aug 26
Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 27, 2024 Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 27, 2024, at 12:00 Indian Standard Time. Reported Earnings • Aug 14
First quarter 2025 earnings released: EPS: ₹0.05 (vs ₹0.70 loss in 1Q 2024) First quarter 2025 results: EPS: ₹0.05 (up from ₹0.70 loss in 1Q 2024). Revenue: ₹47.3m (up 82% from 1Q 2024). Net income: ₹471.0k (up ₹7.63m from 1Q 2024). Profit margin: 1.0% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance. Duyuru • Aug 03
Aspira Pathlab & Diagnostics Limited to Report Q1, 2025 Results on Aug 13, 2024 Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Reported Earnings • May 30
Full year 2024 earnings released: ₹2.60 loss per share (vs ₹0.086 loss in FY 2023) Full year 2024 results: ₹2.60 loss per share (further deteriorated from ₹0.086 loss in FY 2023). Revenue: ₹136.3m (down 5.9% from FY 2023). Net loss: ₹26.7m (loss widened ₹25.8m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. Duyuru • May 20
Aspira Pathlab & Diagnostics Limited to Report Q4, 2024 Results on May 28, 2024 Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2024 results on May 28, 2024 Reported Earnings • Feb 14
Third quarter 2024 earnings released: ₹0.72 loss per share (vs ₹0.43 profit in 3Q 2023) Third quarter 2024 results: ₹0.72 loss per share (down from ₹0.43 profit in 3Q 2023). Revenue: ₹35.6m (down 19% from 3Q 2023). Net loss: ₹7.42m (down 268% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Duyuru • Feb 13
Aspira Pathlab & Diagnostics Limited Announces Resignation of Arvind Bhanushali as Non-Executive, Non-Independent Director and as Member of Audit Committee Aspira Pathlab & Diagnostics Limited informed that Mr. Arvind Bhanushali Non-Executive, Non-Independent Director and as a member of Audit Committee of the Company, has tendered his resignation from the services of the Company due to personal reasons. He shall be relieved from his duties with effect from the close of business hours of February 13, 2024. Duyuru • Feb 02
Aspira Pathlab & Diagnostics Limited to Report Q3, 2024 Results on Feb 10, 2024 Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2024 results on Feb 10, 2024 New Risk • Jan 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹370.0m market cap, or US$4.45m). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Revenue is less than US$5m (₹141m revenue, or US$1.7m). Duyuru • Oct 28
Aspira Pathlab & Diagnostics Limited to Report Q2, 2024 Results on Nov 11, 2023 Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2024 results on Nov 11, 2023 Duyuru • Oct 18
Aspira Pathlab & Diagnostics Limited Appoints Manas Mengar as the Member of Nomination and Remuneration Committee Aspira Pathlab & Diagnostics Limited has appointed Mr. Manas Mengar Independent Director of the Company as the member of Nomination and Remuneration Committee of the Company with effect from October 17, 2023. Name of the Directors: Mr. Avinash Chander Mahajan; Chairman of Nomination and Remuneration Committee; Independent Director, Mrs. Mangala Radha Krishnan Prabhu; Member of Nomination and Remuneration Committee; Independent Director, Mr. Manas Mengar; Member of Nomination and Remuneration Committee; Independent Director. Duyuru • Sep 29
Aspira Pathlab & Diagnostics Limited Announces Completion of Tenure of Subhash Raghunath Salunke as Non-Executive and Independent Director Aspira Pathlab & Diagnostics Limited announced that Mr. Subhash Raghunath Salunke (DIN: 07940567), Non-Executive and Independent Director of the Company has attained age of Seventy Five (75) years on April 19, 2023 and on the completion of his tenure as approved by the member by special resolution as per regulation 17(1A) of the Listing Regulation in the 49th Annual General Meeting of the Company till September 28, 2023, Consequently he ceases to hold Directorship of the Company, Member of the Audit Committee and Nomination and Remuneration Committee with effect from the closure of business hours on September 28, 2023. As per regulation 17(1A) of the Listing Regulation, he ceases to hold the following positions in the Company: Non-Executive and Independent Director, Member of the Audit Committee, Member of the Nomination and Remuneration Committee. Duyuru • Sep 28
Aspira Pathlab & Diagnostics Limited Appoints Manas Mengar as Non-Executive and Independent Director Aspira Pathlab & Diagnostics Limited appointed Manas Mengar as Non-Executive and Independent Director of the Company for a period of 5 (Five) consecutive years in compliance of applicable provisions of Companies Act, 2013 and Listing Regulations. Mr. Manas Mengar has completed his medical educational qualification in MBBS, DNB (Respiratory Diseases), D.M. Pulmonary and Critical Care Medicine. Currently he is serving as a consultant chest Physician, in Jupiter Hospital, Thane and Consultant Intensivist, in Padmashree Hospital, Dombivali. Maharashtra. Duyuru • Aug 15
Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 26, 2023 Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 26, 2023, at 12:00 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2024 earnings released: ₹0.70 loss per share (vs ₹0.28 loss in 1Q 2023) First quarter 2024 results: ₹0.70 loss per share (further deteriorated from ₹0.28 loss in 1Q 2023). Revenue: ₹27.0m (down 8.9% from 1Q 2023). Net loss: ₹7.16m (loss widened 151% from 1Q 2023). Duyuru • Aug 13
Aspira Pathlab & Diagnostics Limited Announces Appointment of Krupali Shah as Company Secretary Cum Compliance Officer Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), Aspira Pathlab & Diagnostics Limited announced that, based on the recommendation of Nomination and Remuneration Committee and the Board of Directors of the Company at its meeting held August 12, 2023 has considered and approved: Appointment of Ms. Krupali Shah as the Company Secretary cum Compliance Officer of the Company. Ms. Krupali Shah (Membership No: A70473) is an Associate Member of the Institute of Company Secretaries of India and a Commerce Graduate from Mumbai University. She has overall experience of 4.5 years in the field of SEBI, Secretarial, Fema laws etc. Duyuru • Jul 28
Aspira Pathlab & Diagnostics Limited to Report Q1, 2024 Results on Aug 12, 2023 Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2024 results on Aug 12, 2023 Duyuru • Jun 26
Aspira Pathlab & Diagnostics Limited Announces the Resignation of Priya Pandey as Company Secretary and Compliance Officer, Key Managerial Personnel Aspira Pathlab & Diagnostics Limited announced that Ms Priya Pandey (Membership No. A66213), Company Secretary and Compliance Officer, Key Managerial Personnel (KMP) of the Company, vide her letter dated June 24, 2023, has tendered her resignation from the services of the Company. She shall be relieved of her duties with effect from the close of business hours of Saturday, June 24, 2023. The Company is in the process of appointing a successor for the position of Company Secretary and Compliance Officer, which shall be duly intimated to the Stock Exchange in due course. Reported Earnings • May 30
Full year 2023 earnings released: ₹0.09 loss per share (vs ₹4.33 profit in FY 2022) Full year 2023 results: ₹0.09 loss per share (down from ₹4.33 profit in FY 2022). Revenue: ₹147.8m (down 24% from FY 2022). Net loss: ₹887.0k (down 102% from profit in FY 2022). Buying Opportunity • May 26
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be ₹39.04, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable. Buying Opportunity • Mar 16
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 29%. The fair value is estimated to be ₹38.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Feb 16
Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹0.84 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.43 (down from ₹0.84 in 3Q 2022). Revenue: ₹44.9m (down 5.1% from 3Q 2022). Net income: ₹4.41m (down 49% from 3Q 2022). Profit margin: 9.8% (down from 18% in 3Q 2022). The decrease in margin was primarily driven by lower revenue. Duyuru • Feb 07
Aspira Pathlab & Diagnostics Limited to Report Q3, 2023 Results on Feb 14, 2023 Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2023 results on Feb 14, 2023 Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Executive Director Nikunj Mange was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Nov 13
Aspira Pathlab & Diagnostics Limited Approves the Change in Designation of Arvind Bhanushali from Executive Director to Non-Executive Director Aspira Pathlab & Diagnostics Limited informed that Board of Directors of the Company, at their meeting held on November 12, 2022, considered and approved the change in Designation of Mr. Arvind Bhanushali from Executive Director to Non-Executive Director on the Board of the Company with effect from November 12, 2022. Duyuru • Nov 06
Aspira Pathlab & Diagnostics Limited to Report Q2, 2023 Results on Nov 12, 2022 Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2023 results on Nov 12, 2022 Valuation Update With 7 Day Price Move • Sep 26
Investor sentiment improved over the past week After last week's 15% share price gain to ₹44.10, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 28x in the Healthcare industry in India. Total loss to shareholders of 38% over the past year. Recent Insider Transactions • Sep 25
Insider recently sold ₹410k worth of stock On the 23rd of September, Paresh Bhanushali sold around 10k shares on-market at roughly ₹41.01 per share. This transaction amounted to 6.1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Valuation Update With 7 Day Price Move • Aug 25
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹44.10, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 25x in the Healthcare industry in India. Total loss to shareholders of 4.2% over the past year. Duyuru • Jul 28
Aspira Pathlab & Diagnostics Limited to Report Q1, 2023 Results on Aug 13, 2022 Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2023 results on Aug 13, 2022 Valuation Update With 7 Day Price Move • Jul 20
Investor sentiment improved over the past week After last week's 15% share price gain to ₹53.70, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 25x in the Healthcare industry in India. Total returns to shareholders of 48% over the past year. Duyuru • May 21
Aspira Pathlab & Diagnostics Limited to Report Q4, 2022 Results on May 28, 2022 Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2022 results on May 28, 2022 Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Executive Director Nikunj Mange was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Apr 19
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Executive Director Nikunj Mange was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Apr 17
Aspira Pathlab & Diagnostics Limited Approves Appointment of Priya Pandey as Company Secretary and Compliance Officer of the Company Aspira Pathlab & Diagnostics Limited at its board meeting held on April 16, 2022 approved the appointment of Ms. Priya Pandey as Company Secretary and Compliance Officer of the company with effect from April 16, 2022. Executive Departure • Oct 03
Company Secretary & Compliance Officer Devyangi Patel has left the company On the 24th of September, Devyangi Patel's tenure as Company Secretary & Compliance Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Devyangi's name. A total of 6 executives have left over the last 12 months. Executive Departure • Sep 29
Company Secretary & Compliance Officer Devyangi Patel has left the company On the 24th of September, Devyangi Patel's tenure as Company Secretary & Compliance Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Devyangi's name. A total of 6 executives have left over the last 12 months. Duyuru • Feb 06
Aspira Pathlab & Diagnostics Limited to Report Q3, 2021 Results on Feb 13, 2021 Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2021 results on Feb 13, 2021 Duyuru • Jan 15
Aspira Pathlab & Diagnostics Limited Announces Resignation of Mamta Mav as Company Secretary & Compliance Officer Aspira Pathlab & Diagnostics Limited announced that Ms. Mamta Mav, have resigned from the position of Company Secretary & Compliance Officer of the Company with effect from closing hours of January 14, 2021. Duyuru • Jul 26
Aspira Pathlab & Diagnostics Limited to Report Q1, 2021 Results on Jul 28, 2020 Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2021 results on Jul 28, 2020